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ABSTRACT
Chronic kidney disease–mineral and bone disorder (CKD–MBD) is one of the many important complications associated with
CKD and may at least partially explain the extremely high morbidity and mortality among CKD patients. The 2009 Kidney
Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline document was based on the best information
available at that time and was designed not only to provide information but also to assist in decision-making. In addition to
the international KDIGO Work Group, which included worldwide experts, an independent Evidence Review Team was
assembled to ensure rigorous review and grading of the existing evidence. Based on the evidence from new clinical trials,
an updated Clinical Practice Guideline was published in 2017. In this review, we focus on the conceptual and practical
evolution of clinical guidelines (from eMinence-based medicine to eVidence-based medicine and ‘living’ guidelines),
highlight some of the current important CKD–MBD-related changes, and underline the poor or extremely poor level of
evidence present in those guidelines (as well as in other areas of nephrology). Finally, we emphasize the importance of
individualization of treatments and shared decision-making (based on important ethical considerations and the
‘best available evidence’), which may prove useful in the face of the uncertainty over the decision whether ‘to treat’ or ‘to
wait’.
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INTRODUCTION
A new definition and classification of chronic kidney disease–
mineral and bone disorder (CKD–MBD) was proposed in 2005 [1]
and later adopted in 2009 in a guideline publication from the
Kidney Disease: Improving Global Outcomes (KDIGO) initiative
entitled ‘KDIGO Clinical Practice Guideline for the Diagnosis,
Evaluation, Prevention and Treatment of CKD–MBD’ [2]. These
steps constituted recognition that CKD–MBD is one of the many
important complications associated with CKD. As is already
well known, CKD–MBD represents a ‘systemic’ condition
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manifested by either one or a combination of laboratory abnor-
malities [calcium, phosphate, parathyroid hormone (PTH) or
vitamin D metabolism], bone abnormalities (turnover, minerali-
zation, volume, linear growth or strength) and vascular and/or
other soft tissue calcifications [1–3]. By linking kidney, bone dis-
ease (evolution of the ‘old’ concept of ‘renal osteodystrophy’,
now restricted to histomorphometric analysis) [1] and cardio-
vascular disease, the CKD–MBD complex represents an attempt
to explain, at least in part, the extremely high morbidity and
mortality of CKD patients [4, 5].
The 2009 KDIGO Clinical Practice Guideline document was
based on the best information available at that time and was
designed not only to provide information but also to assist in
decision-making [2]. It was not intended to define a standard of
care, and it was clearly stated that ‘it should not be construed as
one, nor should it be interpreted as prescribing an exclusive
course of management’ [2]. The KDIGO guidelines were created as
a ‘global’ initiative, and it was recognized that variations in prac-
tice would inevitably and appropriately occur as clinicians take
into account the needs of individual patients, available resources
and limitations unique to an institution or type of practice [2].
Not only did the international KDIGO Work Group include
worldwide experts but in addition, an independent Evidence
Review Team was assembled to ensure a rigorous review and
appraisal of the existing evidence. Briefly, the process included
refining questions, developing the literature search strategy,
extracting data and critically appraising the literature, summa-
rizing the evidence, revising the recommendation statements,
and grading evidence quality and the strength of recommenda-
tions using the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) approach [2, 6].
Therefore, each recommendation was accompanied by the
strength of the recommendation and an evidence grade.
Guideline statements that provided general advice or guidance
(and thus were not based on systematic review) were desig-
nated as ‘not graded’. The guideline development process con-
cluded with an external public review to ensure widespread
input from patients, experts, industry and national organiza-
tions. After the initial publication [2], several national societies
and/or organizations followed-up with commentaries, interpre-
tations, updates and local adaptations [7–9]. Based on the evi-
dence from new clinical trials, an updated Clinical Practice
Guideline was published in 2017 after the Madrid 2013 KDIGO
Controversies Conference determined that there was sufficient
new evidence to support updating some of the previous CKD–
MBD recommendations [10, 11]. This systematic update process
finally resulted in 21 updated recommendations/suggestions,
and several societies have already commented on this update,
drawing attention to remaining critical issues and points
relevant to correct interpretation [11–14] (J. V. Torregrosa et al.,
submitted for publication in the Spanish Society of Nephrology
journal “Nefrologia”). In this review, we will examine the con-
ceptual/practical evolution of clinical guidelines, highlight some
of the important CKD–MBD-related changes and underline
some ethical considerations that may prove of importance in
the face of uncertainty.
EVIDENCE-BASED MEDICINE VERSUS
EMINENCE-BASED MEDICINE
Since the time of Hippocrates, as Djulbegovic and Guyatt
recently remarked in The Lancet [15], medicine has struggled to
balance the uncontrolled experience of ‘healers’ with observa-
tions obtained by rigorous investigation of claims regarding the
effects of health interventions. Dr Guyatt first coined the term
‘eVidence-based medicine’ (EBM) in 1991 [16], contending
that although there is a role for all empirical observations, ran-
domized controlled clinical trials (RCTs), systematic reviews
and meta-analyses provide more trustworthy evidence than do
unsystematic, uncontrolled observations, case reports, biologi-
cal experiments and the experiences of individual clinicians or
experts (‘eMinence-based medicine’ or, even worst, ‘eLoquence-
based medicine’, ‘eLegance-based medicine’ or ‘vehemence-
based medicine’ [17, 18]) (Figure 1). The practice of medicine
should be based on systematic reviews that summarize the
‘best “available” evidence’, even though uncontrolled clinical
experience and incomplete or fragmented physiological reason-
ing have maintained a dominant position as drivers of usual
clinical practice. As a matter of fact, past inadequate research
led to fatal bone marrow transplantation for women with breast
cancer, prophylactic antiarrhythmic therapy in patients with
myocardial infarction and the prescription of hormone replace-
ment therapy in millions of healthy women on the basis of a
hypothetical cardiovascular risk reduction [15, 19–21].
Moreover, evidence should be evaluated in totality rather than
focusing on a selection of evidence that favours a particular
EMINENCE-
based medicine
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FIGURE 1: Schematic representation of eMinence-based medicine vs eVidence-based medicine.
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claim. ‘Anchoring’ is a fact, i.e. once we adopt a belief regarding
a concept, when confronted with new data we tend, on average,
not to move as far from our accustomed position as we should
[22]. If the new data are positive, then the ‘believers’ accept the
data, whereas ‘non-believers’ find some reason to discredit
them (e.g. because data derive from different races, countries or
continents or because of variation and/or validity of different
endpoints) [22]. Similarly, we tend to remember and refer to
studies that confirm our views and ignore those that do not
(and this is a problem when heterogeneity is common) [22]. In
any case, we have to remember that well-conducted systematic
reviews can summarize not only RCTs but also cohort studies,
case–control studies and even case reports [15]. Nevertheless,
results from different systematic reviews and meta-analyses
may also differ substantially [23–28].
EBM integrates the best published scientific evidence (what
the literature says) with clinical expertise (clinical judgment or
what the clinician knows) and patient values, preferences or
expectations (what the patient wants) (Figure 2). An extension
of EBM methodology that is more relevant today is evidence-
based clinical practice, which takes into account the healthcare
setting and circumstances in which we practice. On the other
hand, the GRADE system, first published in 2004 [31], provides a
much more refined hierarchy of evidence, and its use in the
KDIGO Clinical Practice Guidelines for CKD–MBD represented a
very important step forward as compared with previous mineral
metabolism guidelines [32, 33]. GRADE also addresses the
process of moving from evidence to recommendations (Grade
1¼ strong evidence¼ right for all or almost all patients; Grade
2¼weak evidence¼ right for most but not all patients, requiring
presentation of evidence that facilitates shared decision-mak-
ing) (Table 1). Note that the need to consider patients’ values
and preferences is acknowledged [15]. Consequently, although
not all evidence-based practices are alike [34, 35], GRADE has
been adopted by >100 organizations, including the Cochrane
Collaboration, National Institutes of Health, World Health
Organization (WHO) and, obviously, KDIGO.
KDIGO CKD–MBD GUIDELINES
KDIGO CKD–MBD guidelines (from both 2009 and 2017) repre-
sent the most important academic work on the subject to date
(and a major effort in terms of precise use of grammar!),
but given their worldwide potential implications for health
authorities, and also their political, economic and even legal
consequences, it was rather disappointing to see a lack of strong
clinical evidence in almost all areas. This definitely highlights
Evidence-based
Practice/Medicine
Individual Clinical 
Expertise
(Judgment)
What the clinician knows
Patient Values, 
Preferences & 
Expectations
What the patients wants
External
Best (Published) 
Research (Scientific) 
Evidence
What the literature says
FIGURE 2: Schematic representation of evidence-based practice/medicine
(adapted from references [29, 30]).
Table 1. Nomenclature and description for rating guideline recommendations (GRADE) [11, 30]
Implications
GRADEa Patients Clinicians Policy
Level 1
‘We recommend’
Most people in your situation
would want the recommended
course of action, and only a
small proportion would not
Most patients should receive the
recommended course of action
The recommendation can be eval-
uated as a candidate for devel-
oping a policy or a performance
measure
Level 2
‘We suggest’
The majority of people in your sit-
uation would want the recom-
mended course of action, but
many would not
Different choices will be appropri-
ate for different patients. Each
patient needs helps to arrive at a
management decision consis-
tent with her or his values and
preferences
The recommendation is likely to
require substantial debate and
involvement of stakeholders be-
fore policy can be
determined
GRADE Quality of evidence Meaning
A High We are confident that the true effect lies close to the estimate of the effect
B Moderate The true effect is likely to be close to the estimate of the effect, but there is a
possibility that it is substantially different
C Low The true effect may be substantially different from the estimate of the effect
D Very low The estimate of the effect is very uncertain, and often will be far from the
truth
aThe additional category ‘not graded’ is typically used to provide guidance based on common sense or when the topic does not allow adequate application of evidence.
The ungraded recommendations are generally written as simple declarative statements, but are not meant to be interpreted as being stronger recommendations than
level 1 or 2 recommendations.
Within each recommendation the strength of recommendation is indicated as Levels 1,2, or ‘not graded’, and the quality of the supporting evidence is shown as
A,B,C or D.
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the need for rigorous RCTs in this field (as well as others) and
for most of us offers a lesson in the need for humility. Humans
are ‘informavores’ [36], and in an era in which we have moved
from ignorance to infoxication [37, 38], an increasingly sophisti-
cated hierarchy of evidence and systematic summaries of the
best evidence to guide care are of the utmost importance
(Figure 3). However, in the case of CKD–MBD (and most areas of
nephrology), the level of evidence is poor or extremely poor;
nevertheless, we are required to act [42–44].
Not many things really changed in 2017 [11–13, 45]. The new
guidelines are mostly graded as suggestions (Level 2) or are ‘not
graded’ at all. Moreover, the quality of supporting evidence is
mainly low (Grade C). Thus, among all current [‘old’ 2009 (no up-
date needed) and ‘new’ (updated 2017)] recommendations for
‘adults’, only one (old) is graded as Level 1 A evidence (Guideline
4.3.1), namely the ‘recommendation’ that patients with CKD
Stages 1 and 2 with osteoporosis and/or high risk of fracture, as
identified by WHO criteria, should be managed as for the
general population. Two guidelines (old) are graded as 1B: one
recommends that clinical laboratories should inform clinicians
of the actual assay method in use and report any changes in
methods, sample source and handling specifications (Guideline
3.1.6) and the other recommends measuring serum calcium and
phosphate at least weekly, until stable, during the immediate
post-kidney transplant period (Guideline 5.1). Three more revis-
ited guidelines (old) are graded as 1C and recommend: (i) moni-
toring serum levels of calcium, phosphate, PTH and alkaline
phosphatase activity, beginning in CKD Stage 3A; (ii) basing
therapeutic decisions on ‘trends’ rather than a single laboratory
value; and (iii) avoiding the long-term use of aluminium-con-
taining phosphate binders and dialysate aluminium contami-
nation (Guidelines 3.1.1, 3.1.4 and 4.1.7, respectively). An
additional guideline (old) is graded 2A (3.3.2) and ‘suggests’ that
patients with known vascular or valvular calcification should be
considered at the highest vascular risk. Six others [two old and
(at last!) four new] are graded as 2B: Guidelines 3.2.1, 3.2.3, 4.1.6,
4.2.4, 4.2.5 and 4.3.2. These relate to (i and ii) bone mineral den-
sity (BMD) testing to assess fracture risk and suggested circum-
stances to treat CKD patients with CKD Stages 3A and 3B; (iii)
measurements of PTH and bone-specific alkaline phosphatase
to evaluate bone disease (predictors of bone turnover); (iv) the
use of calcimimetics, calcitriol or vitamin D analogues (or com-
binations thereof) in dialysis patients requiring PTH-lowering
therapy (written in alphabetical order); (v) parathyroidectomy
for those who fail to respond to medical treatment; and (vi) re-
striction of the dose of calcium-based phosphate binders in
adult patients receiving phosphate-lowering treatment (impor-
tantly, the evidence grade for this statement has increased from
2C to 2B since the 2009 guidelines). It should be underlined that
the 2009 KDIGO guidelines recommended that the dose of
calcium-based phosphate binders be restricted in the presence
of persistent or recurrent hypercalcaemia (1B) and/or adynamic
bone disease (2C) and/or persistently low serum PTH levels (2C),
as well as in the presence of arterial calcification (2C). Actually,
the last remark represented a step forward since the earlier
2003 National Kidney Foundation Kidney Disease Outcomes
QUality Initiative (NKF KDOQI) guidelines stated that non-cal-
cium-containing phosphate binders were preferred in dialysis
patients with ‘SEVERE’ vascular and/or other soft tissue calcifi-
cations [33]. The evidence grade for use of a dialysate calcium
concentration between 1.25 and 1.50 mmol/L (2.5 and 3.0 mEq/L)
(Guideline 4.1.4) was also upgraded (to 2C from 2D) [2, 11].
The new guidelines included a very important change of par-
adigm in respect of BMD testing. In 2009, it had been suggested
that, in patients with CKD Stages 3–5D, BMD testing should
‘NOT’ be performed routinely because BMD does ‘NOT’ predict
fracture risk as it does in the general population, and BMD does
NOT predict the type of renal osteodystrophy (2B). However,
new evidence from several RCTs now suggests that in such
patients, BMD testing SHOULD BE performed to assess fracture
risk ‘if’ results will impact clinical decisions (Guideline 3.2.1; evi-
dence again graded as 2B despite the very significant change).
This guideline is related to Guideline 4.3.2, which suggests treat-
ment as for the general population in patients with CKD Stages
3A and 3B with PTH in the ‘normal’ range and osteoporosis and/
or high risk of fracture as identified by WHO criteria (2B).
Consequently, there is currently an important debate over the
extent to which these changes represent an important diagnos-
tic and therapeutic challenge for nephrologists (in the absence
of clear-cut treatment evidence) [46, 47], additionally consider-
ing that the inability to perform a bone biopsy may not justify
withholding antiresorptive therapy from patients at high risk of
fracture [11, 48]. This new guideline also begs many questions
with respect to implementation. For example, what exactly are
‘risk factors for osteoporosis’ in CKD patients when CKD itself,
among others, is clearly such a risk? What is the accuracy of the
diagnosis of the underlying bone phenotype? What is the ‘nor-
mal’ range for serum PTH in CKD patients? [12].
It is also worth mentioning that statements in the chapters
devoted to the treatment of CKD–MBD, targeted at lowering
high serum phosphate levels and maintaining serum calcium,
and the treatment of abnormal PTH levels, are mostly graded as
2C or not graded, with the ‘obvious’ clear exceptions mentioned
above. Optimal PTH goals in the non-dialysis CKD setting are
not known; therefore, beyond the avoidance of hypercalcaemia
(Guideline 4.1.3; evidence upgraded to 2C from 2D), the lowering
of elevated phosphate levels ‘towards’ the normal range now
in all CKD stages (2C) and the avoidance of ‘preventive’
phosphate-lowering treatment, the guidelines only suggest
that, in dialysis patients, intact serum PTH levels should be
maintained in the range of approximately two to nine times the
upper normal limit for the assay (2C), and that marked and con-
sistent changes in PTH in either direction even within this range
should prompt initiation of or change in therapy to avoid pro-
gression to values outside of this range (2C) (the so-called
extremes of risk). While the implementation of the guidelines is
not an easy task and misinterpretations or shortcuts are
RCT
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FIGURE 3: Traditional (A) and new (B) evidence-based medicine hierarchies of
evidence (adapted from references [15, 39–41]). Note that systematic reviews are
‘chopped-off’ from the pyramid since a meta-analysis of well-conducted RCTs
at low risk of bias cannot be equated with a meta-analysis of observational stud-
ies at higher risk of bias [41]. Some recent reports suggest that lines separating
the study designs should be wavy instead of straight [41]. NW, Network.
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possible [leading to over- or under-diagnosis and over- or un-
der-treatments (‘therapeutic nihilism’)], it has been docu-
mented that mean serum PTH levels have increased in most
countries since the 2009 KDIGO publication [49].
A further suggestion in the guidelines is that calcitriol and
vitamin D analogues should NOT BE routinely used in adult
patients with CKD Stages 3A–5 who are not on dialysis (2C). This
suggestion is based on the results of the Paricalcitol Capsule
Benefits in Renal Failure-Induced Cardiac Morbidity (PRIMO)
and Effect of paricalcitol on left ventricular mass and function
in CKD (OPERA) studies and some meta-analyses that included
studies performed at a time when a certain degree of hypercal-
caemia was considered useful, in accordance with the previ-
ously available drug armamentarium. The PRIMO and OPERA
studies were negative regarding the primary endpoint (reduc-
tion of left ventricular hypertrophy but NOT the control of sec-
ondary hyperparathyroidism). Thus, these patients were
treated with relatively very high doses of paricalcitol, especially
taking into account the fact that most patients had only minor
or mild elevations of PTH levels [50, 51]. However, somewhat
surprisingly, in the new guidelines, it is considered reasonable
to reserve the use of calcitriol and vitamin D analogues for
patients with CKD Stages 4 and 5 who have ‘severe’ and pro-
gressive hyperparathyroidism. Although this statement is ‘not
graded’, vitamin D is a classic ‘preventive’ and therapeutic ma-
noeuvre that we have been employing (even enforcing!) for
many years [32, 33]. This new guideline calls attention to the
suggestion that a ‘passive’ attitude (with non-native forms of vi-
tamin D) should be adopted until ‘something’ becomes suffi-
ciently ‘severe’ to warrant the initiation of treatment. Moreover,
the perception of ‘severity’ remains at the discretion of the prac-
titioner despite active surveillance. Of note, it is still unknown
what the optimal serum PTH level is in these patients. A differ-
ent reasonable approach is suggested by some (J. V. Torregrosa
et al., submitted for publication in the Spanish Society of
Nephrology journal “Nefrologia”) to avoid an induced and prob-
ably inadequate normalization of serum PTH levels in these
patients without the need for passive ‘waiting’ until something
becomes sufficiently ‘severe’ to consider treatment. Actually,
some degree of secondary hyperparathyroidism may be benefi-
cial in CKD patients (PTH is a phosphaturic hormone and is nec-
essary for a normal bone formation rate) due to the presence of
PTH hyporesponsiveness (PTH resistance) in CKD [52, 53].
Whether these 2017 KDIGO changes will result in a greater
number of patients reaching later PTH extremes of risk or real
improvement in patient-level outcomes remains to be seen.
The rationale for all these KDIGO-suggested interventions is
based, with very few exceptions, on our evolving understanding
of the complex CKD–MBD pathophysiology, the assumed biolog-
ical plausibility for a treatment effect, epidemiological studies
and other considerations [45]. We are used to achieving a
desired target value for an ion or hormone mainly on the basis
of retrospective studies; however, it is becoming clear not only
that the achievement of these artificial goals is difficult [54, 55]
(there are many interactions among biomarkers and among
treatments), but also that the evidence base for them is of lim-
ited value—since, as mentioned before, most are graded as 2C.
This is so even if in some studies (mainly retrospective, post hoc
or using predefined but nominally significant ‘secondary’ out-
comes) it seems that the mortality rates are reduced by the
achievement of certain targets or the use of certain drugs
[56–61]. Therefore, the benefit of achieving the difficult KDOQI
or the more recent KDIGO targets [54, 55], in terms of improve-
ments in hard outcomes or survival, remains to be confirmed in
long-term prospective RCTs [54]. As nicely stated by Drs Chen
and Bushinsky, it would be desirable for us, ‘as a nephrology
community’, to ‘focus our investigative efforts on testing hy-
potheses in RCTs with clinically important endpoints such as
CKD progression, cardiovascular events, fractures or mortality,
which will enable stronger recommendations to be made in the
next revision of the KDIGO CKD–MBD guidelines’ [45].
ETHICAL CONSIDERATIONS
Very significant gaps remain in our knowledge and there is a
danger that the consequences of a ‘misunderstood’ EBM will be
‘therapeutic nihilism’, especially under financial pressure.
Absence of evidence is not evidence of absence (argumentum
ad ignorantiam) [62]. While clinical experience and expert opin-
ion can, of course, be criticized and must be analysed, we
greatly believe that their significance cannot be completely dis-
missed [63]. For instance, in the absence of clear evidence in
some areas (such as antithrombotic therapy in end-stage renal
disease), expert opinion is still very welcome so that nephrolo-
gists are not left alone when facing difficult and sometimes
risky clinical and therapeutic decisions for which supporting ev-
idence is lacking [44]. All these ethical/philosophical/practical
dilemmas actually extend to most areas within general ne-
phrology (Table 2), causing nephrologists to struggle to choose
between passivity (adopting a ‘wait and see’ approach and de-
ciding to act only when Level 1 evidence becomes available) and
an exceedingly proactive attitude based on long-lasting ‘beliefs’
that sometimes are not confirmed [66, 67]. For many reasons,
including the frequent loss of patients (e.g. due to renal trans-
plantation) and the complex nature of uraemia and dialysis,
RCTs in nephrology are and probably will remain extremely
scarce [60, 61]. A variety of additional problems have been de-
scribed with respect to the guidelines and/or EBM [15], including
delays in updating new relevant evidence when it becomes
available (Table 3). ‘Living’ systematic reviews and ‘living’
guideline recommendations [68, 69] may help solving this last
problem. However, unawareness or infoxication, difficulty in the
achievement of goals, limited adherence, disbelief in current
recommendations, sometimes induced by continuously chang-
ing recommendations or significant differences among different
societies that are more or less conservative, misinterpretation
by non-experts and ‘shortcutting’ have been described as addi-
tional difficulties in guidelines [37, 44, 54, 55, 70–73]. In any case,
the methodical analysis of one’s own decision-making is man-
datory. While ‘precision medicine’ in nephrology is still far
away [74] and big data will transform our clinical decision-mak-
ing [75] (some consider that the role of the physician will be en-
hanced, not diminished, as evidence and data grow) [76], the
main ethical principles (Table 4) [77] should be seriously
taken into account. In this context, we believe that both
‘individualization’ of treatments (applying the principles of
non-maleficence and beneficence) and, especially, ‘shared’
decision-making (respecting the patient’s autonomy and social
justice) should help in resolving difficult dilemmas between
‘treating’ or ‘waiting’ in any particular situation.
We should all ‘go to the balcony’ and recognize that, from
that wider perspective, guidelines assist in the provision of rec-
ommendations at the individual personalized (shared!) patient-
level, where straightforward ethical principles may be of valu-
able help (Table 4). As a matter of fact, the most significant
change in the current update is a move towards a more articu-
lated pragmatic and personalized approach to management for
each patient [12, 13]. The attached guideline expert research
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recommendations are also extremely valuable in enabling the
detection of major flaws in current data. As Nicolaus
Copernicus nicely put it ‘to know that we know what we know,
and to know that we do not know what we do not know, that is
true knowledge’. However, while the history of medicine has
sometimes made fools of physicians [20–22], including those ex-
treme advocates of EBM as very nicely reported in the system-
atic review of the parachute gravitational challenge [78],
comparison of the current status of our CKD population with
that in earlier decades clearly suggests that much progress has
been made in all our fields (before and after EBM) and that the
forward momentum will be maintained by following the best
available evidence.
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Table 2. Summary of evidence grades in the 2012 KDIGO glomerulonephritis and 2009 transplant recipient guideline statements compared
with the 2017 CKD–MBD guidelines [64, 65]
Evidence grades
Statements
(glomerular), n (%)
Statements
(transplant), n (%)
Statements
(CKD–MBD), n (%)
1A 6 (3.1) 3 (1.2) 1 (2.2)
1B 22 (11.5) 15 (6.2) 2 (4.3)
1C 17 (8.9) 18 (7.5) 3 (6.5)
1D 0 15 (6.2) 0
Total GRADE 1 (recommendations) 45 (23.5) 51 (21.1) 6 (13)
2A 0 1 (0.4) 1 (2.2)
2B 10 (5.2) 11 (4.6) 6 (13)
2C 51 (26.6) 59 (24.5) 17 (37)
2D 60 (31.3) 76 (31.5) 4 (8.7)
Total GRADE 2 (suggestions) 121 (63.1) 147 (61) 28 (60.9)
Not graded 26 (13.5) 43 (17.8) 12 (26.1)
Total number of statements 192 (100) 241 (100) 46 (100)
Note that the number of statements in CKD–MBD guidelines is (obviously) lower as is the percentage of Grade 1 evidence statements, whereas ‘not graded’ evidence is
more frequent. Regarding the percentage of Grade 2 evidence statements (similar percentage in all guidelines and more frequent than Grade 1), CKD–MBD guidelines
include a higher percentage of 2A–2C statements versus 2D statements (which are more frequent in the other guidelines).
Table 3. Summary of contributions (pros) and criticisms (cons) of Evidence Based Medicine (discussed in references [15, 68, 69])
Pros: contributions Cons: criticisms
Focus on comparative research, over- or underdiagnosis
and over- or undertreatment
Measurements of the quality of care
Improving publishing standards
Ensuring all trials are registered (investigators report
only 50% of trials, publication bias)
Avoiding waste in research production
Upcoming ‘living’ systematic reviews and ‘living’
guideline recommendations
Reductionism of the scientific method
Overly strict adherence to the evidence hierarchy pyramid [improved by the GRADE
framework (see Figure 3 and Table 1)]
Encouragement of ‘cookbook medicine’ (automatic decision-making—algorithms—
discouraging deliberation)
Promotion of rule-based reasoning instead of intuitive and experimental thinking
There is no high-quality evidence that its application has improved patient care
(poor uptake of Evidence Based Medicine in clinical practice)
‘Hijacking’ by commercial interests
Publication bias (only ‘positive’ studies)
Delay in updating new relevant evidence when it becomes available (‘evidence-
practice’ or ‘know–do’ gap)
Table 4. Main ethical principles (adapted from reference [77])
Principle Definition
Non-maleficence Duty to avoid causing harm and to minimize
harm to the patient
Respect for
autonomy
Duty to respect a patient’s right of self-
governance
Beneficence Duty to maximize benefits and to enhance the
patient’s well-being
Justice Duty to treat patients fairly and equitably
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